echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Bispecific antibody epcoritamab yields positive results in LBCL, including in patients who have failed CAR-T cell therapy

    Bispecific antibody epcoritamab yields positive results in LBCL, including in patients who have failed CAR-T cell therapy

    • Last Update: 2022-05-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Biopharmaceutical companies AbbVie and Genmab today announced updated results from a Phase I/II trial evaluating the bispecific antibody epcoritamab in patients with relapsed/refractory large B-cell lymphoma (LBCL).
    efficacy, including several patients who had previously received
    CAR-T cell therapy
    .
    Based on the results of the EPCORE NHL-1 trial, the companies intend to "work with regulatory agencies to determine next steps and continue to evaluate the efficacy of epcoritamab in various hematological malignancies in various clinical trials

    .
    "

    Lymphoma CAR-T

    The EPCORE NHL-1 trial is designed to evaluate epcoritamab in patients with relapsed, advanced or refractory CD20 + mature B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL)
    .
    The study cohort included 157 patients with relapsed/refractory LBCL who had received a median of 3.
    5 lines of prior therapy,
    nearly 40% of whom had previously received CAR-T cell therapy
    .
    The primary endpoint of the Phase II extension of the trial was overall response rate (ORR) as assessed by an independent review committee

    .
    AbbVie and Genmab said the cohort had an ORR of 63.
    1% and a median duration of response of 12 months

    .

    + Nearly 40% of whom received prior CAR-T cell therapy Nearly 40% of whom received prior CAR-T cell therapy AbbVie and Genmab said the ORR for this cohort was 63.
    1% and the median duration of response was 12 months

    .
    AbbVie and Genmab said the cohort had an ORR of 63.
    1% and a median duration of response of 12 months

    .

    The most common grade 3 or 4 treatment-related adverse events included neutropenia, anemia, and thrombocytopenia
    .
    The incidence of cytokine release syndrome (CRS) of any grade is close to 50%, and the incidence of grade 3 CRS is 2.
    5%

    .
     

     

    When the two companies formed a partnership in 2020 to develop next-generation bispecific antibodies, including epcoritamab, AbbVie paid Genmab $750 million upfront
    .
    As part of the deal, Genmab will also receive milestone earnings of up to $3.
    15 billion and 22%-26% of net sales outside the U.
    S.
    and Japan

    .
    Epcoritamab is also being evaluated for overall survival (OS) in patients with relapsed/refractory DLBCL in an ongoing Phase III trial in patients with relapsed/refractory DLBCL

    .

     

    Original source:

    Original source:

    https://firstwordpharma.
    com/story/5549767

    https://firstwordpharma.
    com/story/5549767
    https://firstwordpharma.
    com/story/5549767


    Leave a comment here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.